News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Bone and joint problems news

Show

From To
Bone and joint problems
Bone loss slows, but continues long-term in HIV-positive people on antiretroviral therapy

People with HIV experienced a decrease in bone density at the hip and spine during their first two years after starting antiretroviral therapy (ART). While bone loss

Published
14 September 2015
By
Liz Highleyman
New and experimental HIV treatments
Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

Published
04 September 2015
From
HIVandHepatitis.com
HIV treatment
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
Bone and joint problems
ART: Daily Vitamin D and Calcium Stave Off Bone Loss

Patients with HIV infection who take antiretroviral therapy (ART) can also reduce antiretroviral therapy-related bone loss by 50% by taking daily high-dose vitamin D and calcium supplements, according to a 48-week study.

Published
17 June 2015
From
Medscape
PrEP
Truvada PrEP causes only mild loss of bone mineral density

Treatment with tenofovir/emtricitabine (Truvada) as pre-exposure prophylaxis (PrEP) is associated with small but significant decreases in bone mineral density (BMD), investigators from the landmark iPrEx study report in the

Published
14 May 2015
By
Michael Carter
Bone and joint problems
FRAX fracture prediction tool underestimates fracture risk in people with HIV

The Fracture Risk Assessment Tool (FRAX), an online tool developed by the World Health Organization and used to help guide decisions about who to screen or treat

Published
18 March 2015
By
Theo Smart
Bone and joint problems
Screening for bone fracture risk should be routine for over-40s with HIV, new guidelines recommend

Screening for fracture risk should be a routine part of HIV care for all over-40s, and all postmenopausal women, all men over 50 and people at

Published
02 February 2015
By
Keith Alcorn
Bone and joint problems
The puzzle of thin bones in young MSM

In Amsterdam, researchers have established a large cohort, called AGEhIV, of both HIV-positive and HIV-negative people of similar age and risk behaviours. Young MSM in this study, regardless of HIV infection, were surprisingly at risk for having thinner-than-normal bones.

Published
01 October 2014
From
CATIE
New and experimental HIV treatments
Gilead Sciences: A Preview of Important HIV Drug Study Results

Gilead is running nine phase III studies involving tenofovir alafenamide (TAF), which reflects the importance of the drug to Gilead's future HIV business. It is collecting an enormous amount of clinical data in which to make the case that TAF should be a preferred backbone drug for new and existing HIV patients, as well as patients who cannot use Viread because of pre-existing kidney conditions.

Published
23 September 2014
From
The Street
HIV/HCV co-infection associated with increased risk of osteoporosis and fractures

Co-infection with HIV and hepatitis C virus (HCV) is associated with increased risks of low bone mineral density (BMD) and fracture, investigators report in the

Published
08 July 2014
By
Michael Carter
← Prev1...34567...13Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.